Pretransfusion Hemoglobin Level and Pattern of Iron Chelation of the Transfusion Dependent Thalassemia Patients
Main Article Content
Abstract
Background: Thalassemia is a common hereditary blood disorder in Bangladesh, requiring regular blood transfusions and iron chelation therapy to manage its complications and improve life quality. Objective: The study aimed to evaluate the pretransfusion hemoglobin levels, the pattern of iron chelation therapy, and the associated complications in transfusion-dependent thalassemia patients. Methods: This hospital-based cross-sectional descriptive study was conducted over six months (November 2016 to April 2017) at Rajshahi Medical College Hospital, with 75 transfusion-dependent thalassemia patients. Data were collected through structured questionnaires from patients' parents, and statistical analysis was performed using SPSS (version 16) to assess means, standard deviations, and p-values. Results: The average age of the patients was 7.7±2.3 years, with 57.33% in the 5-10 years age group. The first blood transfusion occurred at 2.5 years. The mean number of blood transfusions was 52.48±23.90 units. Serum ferritin levels were elevated (mean 3638.74±2567.79 ng/ml), and pretransfusion hemoglobin was low (7.2±1.56 gm/dl). Only 9.33% received regular chelation therapy, and 74.67% did not use any form of chelation. Statistical analysis revealed that patients with facial dysmorphism had significantly lower hemoglobin (6.32 gm/dl, p=0.03) and higher serum ferritin (4774.46 ng/ml in stunted patients). Patients with >50 transfusions had a higher serum ferritin level. Additionally, a longer duration of chelation therapy showed a lower serum ferritin level. Conclusion: This study indicates that thalassemia patients often receive transfusions irregularly and exhibit delayed chelation therapy initiation. Most patients fail to adhere to regular chelation despite elevated serum ferritin levels.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
How to Cite
References
Uddin MM, Akteruzzaman S, Rahman T, Hasan AM, Shekhar HU. Pattern of β‐Thalassemia and Other Haemoglobinopathies: A Cross‐Sectional Study in Bangladesh. International Scholarly Research Notices. 2012;2012(1):659191.
Sultana GN, Begum R, Akhter H, Shamim Z, Rahim MA, Chubey G. The complete Spectrum of beta (β) thalassemia mutations in Bangladeshi population. Austin Biomark Diagn. 2016;3(1):1024.
Roy A, Shengelia L. A review on situation of congenital disorders and access to community genetics services in Bangladesh. Ann Clin Lab Res. 2016;4(2):1-4.
Malakar R, Kour M, Malviya SN, Dangi CB. A review on: Β-Thalassemia. World journal of pharmaceutical research. 2016 Mar 28;5(6):432-5.
Nienhuis AW, Nathan DG. Pathophysiology and clinical manifestations of the β-thalassemias. Cold Spring Harbor perspectives in medicine. 2012 Dec 1;2(12): a011726.
Porter J, Viprakasit V, Kattamis A. Iron overload and chelation. Guidelines for the management of transfusion dependent thalassaemia, 3rd ed. Thalassaemia international federation. 2014 Sep 8:42-97.
Saliba AN, Harb AR, Taher AT. Iron chelation therapy in transfusion-dependent thalassemia patients: current strategies and future directions. Journal of blood medicine. 2015 Jun 17:197-209.
Oikonomidou PR, Casu C, Rivella S. New strategies to target iron metabolism for the treatment of beta thalassemia. Annals of the New York Academy of Sciences. 2016 Mar;1368(1):162-8.
Musallam KM, Cappellini MD, Wood JC, Taher AT. Iron overload in non-transfusion-dependent thalassemia: a clinical perspective. Blood reviews. 2012 Apr 1;26:S16-9.
Sarker NR, Ghosh AK, Saha SK, Shahriar A. Recent advances in the management of Thalassaemia: A Review Update. Journal of Shaheed Suhrawardy Medical College. 2014;6(1):31-7.
Rahman M, Irshadullah NM, Ahmed M, Kabir AL, Begum M, Mostafa AG, Khan AH. Prevalence of iron deficiency in thalassemia trait: a study in BSMMU, Dhaka. Bangladesh Journal of Medicine. 2014;25(1):13-6.
Karim MF, Ismail M, Hasan AM, Shekhar HU. Hematological and biochemical status of Beta-thalassemia major patients in Bangladesh: A comparative analysis. International journal of hematology-oncology and stem cell research. 2016 Jan 1;10(1):7.
Faizan-ul-Haq MM, Khan MM, Sajid S, Sarfaraz A, Nasir N, Nazim A, Kamran G, Maqsood B, Ahmed A. Frequency and awareness of Thalassemia in families with cousin marriages: A study from Karachi, Pakistan. In14th International Conference on 2016 Mar 14 (p. 279).
Chatterjee T, Chakravarty A, Chakravarty S, Chowdhury MA, Sultana R. Mutation spectrum of β-thalassemia and other hemoglobinopathies in Chittagong, Southeast Bangladesh. Hemoglobin. 2015 Nov 2;39(6):389-92.
Adekile AD, Azab AF, Al-Sharida SI, Al-Nafisi BA, Akbulut N, Marouf RA, Mustafa NY. Clinical and molecular characteristics of non-transfusion-dependent thalassemia in Kuwait. Hemoglobin. 2015 Sep 3;39(5):320-6.
Angelucci E, Pilo F. Management of iron overload before, during, and after hematopoietic stem cell transplantation for thalassemia major. Annals of the New York Academy of Sciences. 2016 Mar;1368(1):115-21.
Borgna-Pignatti C, Marsella M. Iron chelation in thalassemia major. Clinical therapeutics. 2015 Dec 1;37(12):2866-77.
Poggiali E, Cassinerio E, Zanaboni L, Cappellini MD. An update on iron chelation therapy. Blood Transfusion. 2012 Oct;10(4):411.
Hider RC, Kong X. Iron: effect of overload and deficiency. Interrelations between essential metal ions and human diseases. 2013:229-94.
Mamtani M, Kulkarni H. Recent Advances in the Treatment of β-Thalassemia Major. Frontiers in Clinical Drug Research: Hematology: Volume 1. 2014 Jun 17:225-76.
Abu Samra O, Auda W, Kamhawy H, Al-Tonbary Y. Impact of educational programme regarding chelation therapy on the quality of life for B-thalassemia major children. Hematology. 2015 Jun 1;20(5):297-303.